Data-driven medicine company SOPHiA GENETICS has completed the acquisition of French tech company Interactive Biosoftware (IBS).
IBS created Alamut, which is said to be the most used decision support software for clinical genomic data interpretation.
Currently deployed in more than 450 hospitals, the software is complementary to SOPHiA GENETICS’ offering.
The acquisition is aimed at further accelerating the adoption of data-driven medicine across the globe.
Interactive Biosoftware CEO and founder André Blavier said: “Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs.
“It is great to join SOPHiA GENETICS unique approach and position to accelerate Data-Driven Medicine’s adoption.”
With the latest acquisition, SOPHiA GENETICS will be able to reinforce its proposal to continuously support hospitals and patients with powerful technologies.
Following the deal, Interactive Biosoftware’s expertise and teams are set to join SOPHiA GENETICS’ workforce.
SOPHiA GENETICS CEO and co-founder Jurgi Camblong said: “We are very excited about the acquisition of Interactive Biosoftware. Both SOPHiA AI and Alamut are technologies trusted by the healthcare community and focus on patient-centric innovation.
“The addition of Alamut marks a big step in our aim to help clinicians better diagnose patients equally. With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge.”
SOPHiA GENETICS has developed SOPHiA AI, the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients.
